Exemestane

Drugs

Volumn 58, Issue 4, 1999, Pages 675-680

  Scott, Lesley J ^a   Wiseman, Lynda R ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE; ESTRADIOL; ESTRONE; ESTRONE SULFATE; EXEMESTANE; FORMESTANE; MEGESTROL; TAMOXIFEN;

ABDOMINAL PAIN; ALOPECIA; ANOREXIA; AREA UNDER THE CURVE; BINDING SITE; BODY WEIGHT DISORDER; BREAST CANCER; CLINICAL TRIAL; CONSTIPATION; DEPRESSION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG TOLERABILITY; DYSPEPSIA; ENZYME INACTIVATION; ESTRADIOL BLOOD LEVEL; ESTRONE BLOOD LEVEL; FATIGUE; FEMALE; HEADACHE; HOT FLUSH; HUMAN; INSOMNIA; LEG EDEMA; NAUSEA; NONHUMAN; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; RASH; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL TIME; SWEATING; VERTIGO; WEIGHT GAIN;

ANDROSTADIENES; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS; ENZYME INHIBITORS; FEMALE; HUMANS; POSTMENOPAUSE;

EID: 0032757904     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199958040-00007     Document Type: Review

References (24)

1. 1. di-Salle E, Giudici D, Briatico G, et al. Novel irreversible aromatase inhibitors. Ann N Y Acad Sci 1990; 595: 357-67
2. 2. di-Salle E, Giudici D. Ornati G, et al. 4-Aminoandrostenedione derivatives: a novel class of irreversible aromatase inhibitors. Comparison with FCE-24304 and 4-hydroxyandrostenedione, J Steroid Biochem Mol Biol 1990 Nov 20; 37: 369-74
3. 3. Giudici D, Ornati G, Briatico G, et al. 6-Methylenandrosta-1,4-diene-3,17-dione (FCE 24304): a new irreversible aromatase inhibitor. J Steroid Biochem 1988; 30: 391-4
4. 4. di-Salle E, Briatico G, Giudici D, et al. Novel aromatase and 5 α-reductase inhibitors. J Steroid Biochem Mol Biol 1994; 49: 289-94
5. 5. Zaccheo T, di-Salle E. Effect of the irreversible aromatase FCE 24304 on DMBA-induced mammary tumors in ovariectomized rats treated with testosterone. Cancer Chemother Pharmacol 1989: 25: 95-8
6. 6. Evans TR, di-Salle E, Ornati G, et al. Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women. Cancer Res 1992; 52: 5933-9
7. 7. Geisler J, King N, Anker G. et al. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin Cancer Res 1998 Sep; 4: 2089-93
8. 8. Johannessen DC, Engan T, di-Salle E, et al. Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study. Clin Cancer Res 1997 Jul; 3: 1101-8
9. 9. Paridaens R, Thomas J, Wildiers J, et al. Safety, activity and estrogen inhibition by exemestane in postmenopausal women with advanced breast cancer: a phase I study. Anticancer Drugs 1998 Sep; 9: 675-83
10. 10. Castelli MG, Cocchiara G, Zurlo MG, et al. Excretion balance and absorption of 14C-exemestane in animals and humans [abstract no. 73]. J Endocrinol Invest 1994; 17 (3 Suppl. I): 76
11. 11. Poggesi I, Allievi C, Strolin Benedetti M, et al. Relative bioavailability and pharmacokinetics of two different formulations of exemestane, a new aromatase inhibitor [abstract no. 76]. J Endocrinol Invest 1994; 17 (3 Suppl. I): 79
12. 12. Persiani S, Poggesi I, Cicioni P, et al. Pharmacokinetics of repeated low-doses of exemestane (1, 2.5, 5 and 10mg) in postmenopausal healthy volunteers. [abstract no. 952]. Eur J Cancer 1995; 31 Suppl. 5: s198
13. 13. Poggesi I, Jannuzzo MG, di-Salle E, et al. Effect of food and formulation on the pharmacokinetics (PK) and pharmacodynamics (PD) of a single oral dose ol exemestane (Aromasin™, EXE) [abstract no. 741]. Proc Am Soc Clin Oncol 1999; 18: 193a
14. 14. Cocchiara G, Allievi C, Berardi A, et al. Urinary metabolism of exemestane, a new aromatase inhibitor, in rat, dog, monkey and human volunteers [abstract no. 75]. J Endocrinol Invest 1994; 17 (3 Suppl. I): 78
15. 15. Thürlimann B, Paridaens R, Serin D, et al. Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study. Eur J Cancer A 1997 Oct; 33: 1767-73
16. 16. Jones S, Chang A, Lusch C, et al. A phase II confirmatory study of antitumour efficacy and safety of exemestane as third-line hormonal treatment of postmenopausal patients with metastatic breast cancer refractory to tamoxifen and megace™ [abstract no. 439]. Breast Cancer Res Treat 1998; 50 (3): 305
17. 17. Lonning PE, Bajetta E, Murray R, et al. A phase II study of exemestane in metastatic breast cancer patients failing nonsteroidal aromatase inhibitors [abstract no. 435]. Breast Cancer Res Treat 1998; 50 (3): 304
18. 18. Jones S, Vogel C, Fehrenbacher L, et al. A phase II study of antitumor efficacy and safety of exemestane as third-line hormonal treatment of postmenopausal patients with metastatic breast cancer refractory to tamoxifen and Megace™ [abstract no. 64p]. Ann Oncol 1998; 9 Suppl. 4: 13
19. 19. Kvinnsland S, Anker G, Dirix LY, et al. Activity of exemestane, an irreversible, oral, aromatase inhibitor in metastatic postmenopausal breast cancer patients failing tamoxifen [abstract no. 408]. Eur J Cancer 1998 Sep; 34 Suppl. 5: s91
20. 20. Jones S, Belt R, Cooper B, et al. A phase II study of antitumour efficacy and safety of exemestane as a second-line hormonal treatment of postmenopausal patients with metastatic breast cancer refractory to tamoxifen [abstract]. 21st Breast Cancer Symposium; 1998 Dec 12-15; San Antonio, Texas
21. 21. Kaufmann M, Bajetta E, Dirix LY, et al. Survival advantage of exemestane (EXE, Aromasin® over megestrol acetate in postmenopausal women with advanced breast cancer refractory to tamoxifen: results of a phase III randomised double-blind study [abstract no. 412]. Proc Am Soc Clin Oncol 1999; 18: 109a
22. 22. Kaufmann M, Aromasin™ versus Megace™: improved outcomes [abstract]. In: Proceedings of 1st Milan Breast Cancer Conference; 1999 Jun 16; Milan: 6-7
23. 23. Tedeschi M, Kvinnsland S, Jones SE, et al. Hormonal therapy in breast cancer and predominant visceral disease: effectiveness of the new oral aromatase inactivator, Aromasin™ (Exemestane), in advanced breast cancer patients having progressed on antiestrogens [abstract]. In: Proceedings of European Cancer Conference: 1999 Sep 12-16: Vienna
24. 24. Kaufman M. Exemestane versus megestrol acetate in postmenopausal patients with metastatic breast cancer, failing tamoxifen: a phase III, double-blind, randomized, parallel-group, comparative study. Pharmacia & Upjohn, Milan, 1998. Report no.:94-OEXE-018. (Data on file)